arrow
J

José M. Mato

ciberehd
H指数:89
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interplay among lipoprotein(a), hepatic and vascular damage in individuals with metabolic dysfunction

脂蛋白(a)、肝脏损伤和血管损伤在代谢功能障碍个体中的相互作用

2025-11-260
OAAI
Age- and sex-specific lipoprotein profiles in general and cardiometabolic population cohorts

年龄和性别特异的脂蛋白谱在一般和心血管代谢人群队列中的研究

2025-11-080
OAAI
S-adenosylmethionine deficit disrupts very low-density lipoprotein metabolism promoting liver lipid accumulation in mice

S-腺苷甲硫氨酸缺乏会破坏极低密度脂蛋白代谢,促进小鼠肝脏脂质积累。

2025-05-010
OAAI
Multi-Omics Biomarkers for Predicting Therapeutic Efficacy in Inflammatory Bowel Disease: Advancing Towards Tailored Treatments
2025-01-220
PRE
Identification of metabolic predictive biomarkers of response to Inflammatory Bowel Disease treatment
2025-01-220
PRE
The role of forkhead box M1-methionine adenosyltransferase 2 A/2B axis in liver inflammation and fibrosis
2024-09-270
OAAI
Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
2024-09-260
PRE
MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics
2024-07-240
OAAI
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

基于与人类代谢功能障碍相关的脂肪变性肝病 (MASLD) 的接近程度,对小鼠饮食模型进行无偏排名

2024-06-1233
OA
Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function
2023-09-018
OAAI
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
2023-07-2423
OAAI